• Regulatory NewsRegulatory News

    FDA releases draft guidances on developing rhinosinusitis drugs, colonoscopy bowel preps

    The US Food and Drug Administration (FDA) has recently released two draft guidances: one with advice for sponsors on the development of drugs for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), and another offering efficacy and safety considerations for the development of bowel cleansing products for colonoscopy.     Guidance on CRSwNP drugs   The agency provided recommendations for sponsors involved in a CRSwNP drug’s development, including d...